Mass Spectrometry-based Protein Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Signatures in Pancreatic Cancer - Biognosys

Mass Spectrometry-based Protein Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Signatures in Pancreatic Cancer

Poster presented at SITC 2022

Presenter: Nigel Beaton
In collaboration with the Parker Institute for Cancer Immunotherapy (PICI)

Back to Resources overview

Helpdesk

Access our knowledge base with relevant resources and guiding information.

Contact